Art. -Nr.: HY-124372

JNJ-46356479

Name: JNJ-46356479
Brand: MedChemExpress
SKU: HY-124372
Price: 460.00 USD
Availability: InStock
Rating: 5 (1 reviews)

Kundenbewertung

Based on 1 Customer Validation

JNJ-46356479 is a blood-brain barrier-penetrant mGluR2/3 allosteric activator. JNJ-46356479 binds to the mGluR2 PAM site to enhance mGluR2 activity, thereby inhibiting presynaptic glutamate release and modulating adenylate cyclase (Adenylate Cyclase), calcium channel (CRAC Channel) activity, and neuronal excitability. JNJ-46356479 exhibits anticonvulsant activity in psychomotor seizures and corneal kindling, and can be used in the study of schizophrenia and epilepsy.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit : 99.77%
CAS. Nr.: 1254979-66-2
Formel: C₂₂H₂₂F₅N₅
Molecular Weight:451.44

Speicherung:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

JNJ-46356479 Chemical Structure

CAS. Nr.: 1254979-66-2

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- Parmacokinetics
- In Vivo
Chemical Information
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

IC₅₀ & Target

^[1]

mGluR2

mGluR3

Alle mGluR Isoform-spezifische Produkte anzeigen :

Cellular Effect

Cell Line	Type	Value	Description	References
CHO	EC₅₀	78 nM Compound: 27; JNJ-46356479	Positive allosteric modulation of human mGlu2 receptor expressed in CHO cell membranes assessed as potentiation of glutamate-induced effect incubated for 30 mins prior to [35S]GTPgamma addition measured after 30 mins by scintillation counting method Positive allosteric modulation of human mGlu2 receptor expressed in CHO cell membranes assessed as potentiation of glutamate-induced effect incubated for 30 mins prior to [35S]GTPgamma addition measured after 30 mins by scintillation counting method	[PMID: 27579727]
CHO-K1	EC₅₀	1410 nM Compound: 27; JNJ-46356479	Positive allosteric modulation at human mGlu2 receptor N735D mutant expressed in CHO-K1 cells assessed as potentiation of glutamate-induced effect incubated for 30 mins prior to [35S]GTPgamma addition measured after 30 mins by scintillation counting metho Positive allosteric modulation at human mGlu2 receptor N735D mutant expressed in CHO-K1 cells assessed as potentiation of glutamate-induced effect incubated for 30 mins prior to [35S]GTPgamma addition measured after 30 mins by scintillation counting metho	[PMID: 27579727]
CHO-K1	EC₅₀	2340 nM Compound: 27; JNJ-46356479	Positive allosteric modulation at human mGlu2 receptor W773A mutant expressed in CHO-K1 cells assessed as potentiation of glutamate-induced effect incubated for 30 mins prior to [35S]GTPgamma addition measured after 30 mins by scintillation counting metho Positive allosteric modulation at human mGlu2 receptor W773A mutant expressed in CHO-K1 cells assessed as potentiation of glutamate-induced effect incubated for 30 mins prior to [35S]GTPgamma addition measured after 30 mins by scintillation counting metho	[PMID: 27579727]
CHO-K1	EC₅₀	45.7 nM Compound: 27; JNJ-46356479	Positive allosteric modulation of wild-type human mGlu2 receptor expressed in CHO-K1 cells assessed as potentiation of glutamate-induced effect incubated for 30 mins prior to [35S]GTPgamma addition measured after 30 mins by scintillation counting method Positive allosteric modulation of wild-type human mGlu2 receptor expressed in CHO-K1 cells assessed as potentiation of glutamate-induced effect incubated for 30 mins prior to [35S]GTPgamma addition measured after 30 mins by scintillation counting method	[PMID: 27579727]
CHO-K1	EC₅₀	6610 nM Compound: 27; JNJ-46356479	Positive allosteric modulation at human mGlu2 receptor F643A mutant expressed in CHO-K1 cells assessed as potentiation of glutamate-induced effect incubated for 30 mins prior to [35S]GTPgamma addition measured after 30 mins by scintillation counting metho Positive allosteric modulation at human mGlu2 receptor F643A mutant expressed in CHO-K1 cells assessed as potentiation of glutamate-induced effect incubated for 30 mins prior to [35S]GTPgamma addition measured after 30 mins by scintillation counting metho	[PMID: 27579727]
CHO-K1	EC₅₀	977 nM Compound: 27; JNJ-46356479	Positive allosteric modulation at wild type human mGlu2 receptor L732A mutant expressed in CHO-K1 cells assessed as potentiation of glutamate-induced effect preincubated for 30 mins prior to glutamate challenge measured after 30 mins by [35S]GTP-gammaS bi Positive allosteric modulation at wild type human mGlu2 receptor L732A mutant expressed in CHO-K1 cells assessed as potentiation of glutamate-induced effect preincubated for 30 mins prior to glutamate challenge measured after 30 mins by [35S]GTP-gammaS bi	[PMID: 27579727]

In Vitro

Glutamate Release or Receptors

JNJ-46356479 competitively binds the mGluR2 PAM site in Wistar rat cortical membranes, fully displacing ³H-JNJ-42203993 with an IC₅₀ of 107 nM^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Parmacokinetics

Species	Dose	Route	Plasma Concentration
Mice^[5]	2.5 (JNJ-46356479); 75 (VPA) (i.p.) mg/kg	s.c.	0.48 μg/mL
Mice^[5]	5 (JNJ-46356479); 150 (VPA) (i.p.) mg/kg	s.c.	0.85 μg/mL
Mice^[5]	10 (JNJ-46356479); 300 (VPA) (i.p.) mg/kg	s.c.	1.77 μg/mL
Mice^[5]	2.5 (JNJ-46356479); 12.5 (LTG) (i.p.) mg/kg	s.c.	0.38 μg/mL
Mice^[5]	5 (JNJ-46356479); 25 (LTG) (i.p.) mg/kg	s.c.	0.99 μg/mL
Mice^[5]	10 (JNJ-46356479); 50 (LTG) (i.p.) mg/kg	s.c.	2.19 μg/mL

In Vivo

ApoptosisGlutamate Release or ReceptorsOxidative StressOthers

Apoptosis

JNJ-46356479 (10 mg/kg; s.c.; daily; 2 weeks) administered in adulthood partially reverses working memory and social deficits and modulates parvalbumin-positive neurons, c-Fos-positive cells, and apoptotic protein levels in a postpartum NMDA (HY-17551) receptor antagonist mouse model of schizophrenia-like phenotypes^[1].
JNJ-46356479 (10 mg/kg; s.c.; once daily; from PND 80 throughout the study period) is associated with low PFC caspase-3 levels and a low PFC Bax/Bcl-2 ratio in non-induced C57BL/6J mice^[6].
JNJ-46356479 (10 mg/kg; s.c.; once daily; from PND 80 throughout the study period) partially restores PFC Bcl-2 levels and the Bax/Bcl-2 ratio, and attenuates the induced pro-apoptotic state in a postpartum-induced C57BL/6J mouse model of schizophrenia^[6].

Glutamate Release or Receptors

JNJ-46356479 (4 mg/kg; i.v.; single injection; 30 min after radiotracer injection during the scan) does not displace ¹¹C-JNJ-42491293 binding in the brains of wild-type rats and mGluR2 knockout rats^[2].
JNJ-46356479 (10 mg/kg; s.c.; daily; PND 35-60) ameliorates cognitive and social deficits and normalizes hippocampal c-Fos immunoreactivity in a postpartum NMDA receptor antagonist C57BL/6J mouse model of schizophrenia^[3].
JNJ-46356479 (10 mg/kg; s.c.; once daily; PND 35 to PND 60) administered during adolescence to C57BL/6J mice postnatally exposed to an NMDA receptor antagonist decreases hippocampal VGLUT1 levels in the CA1 and CA3 regions, partially reversing the NMDA receptor antagonist-induced elevation of this glutamatergic synaptic marker^[4].

Oxidative Stress

JNJ-46356479 (10 mg/kg; s.c.; chronic; PND 35 to 60) administered during adolescence reverses cognitive and social impairments and attenuates neuronal marker and nitrosative stress alterations in a postpartum NMDA receptor antagonist mouse model of schizophrenia-like phenotype^[1].

Others

JNJ-46356479 (0.5-20 mg/kg; s.c.; single injection; 0.5 h before testing) produces dose-dependent seizure protection in the 6-Hz 32-mA model in adult male CF-1 mice, with an ED₅₀ of 2.8 mg/kg^[5].
JNJ-46356479 (2.5-20 mg/kg; s.c.; single injection; 0.5 h before testing) is active in the more pharmacoresistant 6-Hz 44-mA model in adult male CF-1 mice, with an ED₅₀ of 10.2 mg/kg^[5].
JNJ-46356479 (0.3-5.1 mg/kg; s.c.; single injection; 0.5 h before testing) co-administered with LEV (11.3-271.5 mg/kg; i.p.; single injection; 1 h before testing) produces efficacy greater than the predicted additive effect at 1:1, 1:3, and 3:1 fixed-dose ratios in the 6-Hz 44-mA model in adult male CF-1 mice^[5].
JNJ-46356479 (20-30 mg/kg; s.c.; single dose; 0.5 h before testing) combined with LEV (3 mg/kg; i.p.; single dose; 1 h before testing) produces complete seizure protection in the adult male CF-1 mouse corneal kindling model, with all mice protected at 30 mg/kg JNJ-46356479 plus 3 mg/kg LEV^[5].
JNJ-46356479 (2.5-10 mg/kg; s.c.; single injection; 0.5 h before testing) combined with Valproic acid (VPA) (HY-10585) (37.5-300 mg/kg; i.p.; single injection; 0.25 h before testing) produces additive rather than synergistic anticonvulsant protection in the 6-Hz 44-mA model in adult male CF-1 mice^[5].
JNJ-46356479 (2.5-10 mg/kg; s.c.; single injection; 0.5 h before testing) combined with Lamotrigine (LTG) (HY-B0495) (12.5-50 mg/kg; i.p.; single injection; 1 h before testing) produces additive rather than synergistic seizure protection in the 6-Hz 44-mA model in adult male CF-1 mice^[5].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

C57BL6J (male and female)^[1]
Dosage:

10 mg/kg
Administration:

s.c.; daily; 2 weeks during adulthood (PND > 80; table reports PND 80)
Result:

Working memory partially recovered (Y-maze).
Social motivation and social memory increased (TCST and 5T-SMT).
Parvalbumin-positive neurons increased.
c-Fos-positive neurons decreased.
Proapoptotic protein levels decreased.
Table 2 reported increased working memory, increased social motivation, increased social memory, increased parvalbumin-positive neurons, decreased c-Fos-positive neurons, and decreased proapoptotic protein levels.

Animal Model:

C57BL6J (male and female)^[1]
Dosage:

10 mg/kg
Administration:

s.c.; chronically; PND 35 to 60
Result:

Working memory improved.
Social motivation increased.
Social memory increased.
Parvalbumin-positive neurons increased.
c-Fos-positive neurons increased.
Nitrosative stress decreased.
Effects were observed in adult mice and maintained during adulthood.
Table 2 reported increased working memory, increased social motivation, increased social memory, increased parvalbumin-positive neurons, increased c-Fos-positive neurons, and decreased nitrosative stress.

Animal Model:

wildtype (mGluR2 WT littermate; weight 200-600 g)^[2]
Dosage:

4 mg/kg
Administration:

i.v.; single injection; during scanning at 30 min after radiotracer injection
Result:

No displacement of 11C-JNJ-42491293 binding was observed after JNJ-46356479 (4 mg/kg, i.v.) in wildtype rats.

Animal Model:

mGluR2 knockout (weight 200-600 g)^[2]
Dosage:

4 mg/kg
Administration:

i.v.; single injection; during scanning at 30 min after radiotracer injection
Result:

No displacement of 11C-JNJ-42491293 binding was observed after JNJ-46356479 (4 mg/kg, i.v.) in mGluR2 knockout rats.

Animal Model:

C57BL/6J (male and female; postnatal NMDA receptor antagonist model; JNJ-46356479 administration during PND 35-60; behavioral testing at PND >90)^[3]
Dosage:

10 mg/kg
Administration:

s.c.; daily; PND 35-60
Result:

In the Novel Object Recognition test, JNJ-46356479 mice and NMDA receptor antagonist + JNJ-46356479 mice showed preference for the novel object; NMDA receptor antagonist-exposed mice did not show this preference, and this preference was recovered by JNJ-46356479.
In the three-chamber social novelty test, JNJ-46356479 mice showed preference for the novel animal, and NMDA receptor antagonist + JNJ-46356479 mice recovered this preference.
In the sociability phase, JNJ-46356479 mice preferred a familiar littermate over a toy mouse.
In the five-trial social memory test, the JNJ-46356479 group showed a progressive reduction in time exploring the same animal across trials 1-4: 18.0 s, 13.8 s, 10.2 s, and 7.5 s, respectively.
After four trials, JNJ-46356479 and NMDA receptor antagonist + JNJ-46356479 mice showed increased interaction with a novel mouse in the fifth trial; NMDA receptor antagonist + JNJ-46356479 mice recovered interest in the novel animal.
In the Y-maze, JNJ-46356479 animals showed spontaneous alternation around 80%.
In the rotarod acceleration cycle, JNJ-46356479 mice showed a lower latency to fall compared with controls.
NMDA receptor antagonist + JNJ-46356479 mice recovered prehensile reflex and traction capacity to control levels.
In the mPFC, the NMDA receptor antagonist reduced PV+ interneuron density by almost 25%; the NMDA receptor antagonist + JNJ-46356479 group was included in PV/c-Fos analyses and representative confocal images, while the NMDA receptor antagonist + comparator group recovered control PV values; mPFC c-Fos differences between groups were not significant.
In the hippocampus, JNJ-46356479 normalized c-Fos immunoreactivity in sections DG, CA1, CA2, and CA3, completely reversing the up to 40% NMDA receptor antagonist-induced reduction in c-Fos expression; Bonferroni comparisons showed differences between the NMDA receptor antagonist and NMDA receptor antagonist + JNJ-46356479 groups in DG, CA1, CA2, and CA3.
No significant differences in PV+ cells were detected between groups.

Animal Model:

C57BL/6J (male and female; administered during adolescence PND 35-60 and assessed in adulthood PND 120)^[4]
Dosage:

10 mg/kg
Administration:

s.c.; once daily; PND 35 to PND 60
Result:

In NMDA receptor antagonist-exposed mice, VGLUT1 levels were increased in all HPC regions, with significant increases in CA3 and almost significant increases in CA1 versus control.
Administration in NMDA receptor antagonist-exposed mice restored VGLUT1 levels toward control levels in the hippocampus.
Significantly reduced VGLUT1 levels in hippocampal CA1 and CA3 compared with NMDA receptor antagonist+vehicle.
In CA3, VGLUT1 levels in NMDA receptor antagonist+JNJ-46356479 mice were significantly lower than in NMDA receptor antagonist+clozapine mice.
In the PFC, no significant differences were found in VGLUT1, GAD65/67, or their ratio.
No significant differences were found in GAD65/67 levels or in the VGLUT1/GAD65-67 ratio in any HPC region.
No significant differences between groups survived Bonferroni correction in the expression analysis of 240 selected glutamate/GABA pathway genes.

Animal Model:

CF-1 (adult male, 25-40 g)^[5]
Dosage:

0.5, 2.5, 5, 10, and 20 mg/kg
Administration:

s.c.; single injection; 0.5 h before testing
Result:

In the 6-Hz 32-mA assay, JNJ-46356479 produced seizure protection as follows: 0.5 mg/kg = 1/8 protected; 2.5 mg/kg = 7/16 protected; 5 mg/kg = 8/12 protected; 10 mg/kg = 7/8 protected; 20 mg/kg = 8/8 protected.
Rotarod failures were: 0.5 mg/kg = 0/8; 2.5 mg/kg = 0/16; 5 mg/kg = 0/12; 10 mg/kg = 0/8; 20 mg/kg = 1/8.
ED₅₀ (95% CI) = 2.8 mg/kg (1.3-4.3).

Animal Model:

CF-1 (adult male, 25-40 g)^[5]
Dosage:

2.5, 10, 15, and 20 mg/kg
Administration:

s.c.; single injection; 0.5 h before testing
Result:

In the 6-Hz 44-mA assay, JNJ-46356479 produced seizure protection as follows: 2.5 mg/kg = 0/8 protected; 10 mg/kg = 4/8 protected; 15 mg/kg = 7/8 protected; 20 mg/kg = 8/8 protected.
Rotarod failures were: 2.5 mg/kg = 0/8; 10 mg/kg = 0/8; 15 mg/kg = 0/8; 20 mg/kg = 1/8.
ED₅₀ (95% CI) = 10.2 mg/kg (3.1-12.4).

Animal Model:

CF-1 (adult male, 25-40 g)^[5]
Dosage:

20 or 30 mg/kg (JNJ-46356479); 3 mg/kg (LEV)
Administration:

s.c. for JNJ-46356479 and i.p. for LEV; single dose; 0.5 h before testing for JNJ-46356479 and 1 h before testing for LEV
Result:

20 mg/kg alone produced 5/16 protected (31% protected).
30 mg/kg alone produced 3/12 protected (25% protected).
LEV 3 mg/kg + JNJ-46356479 20 mg/kg produced 7/10 protected (70% protected).
LEV 3 mg/kg + JNJ-46356479 30 mg/kg produced 10/10 protected (100% protected).
No notable motor toxicity was observed after JNJ-46356479 alone or in combination in corneal kindled mice.

Animal Model:

CF-1 (adult male, 25-40 g)^[5]
Dosage:

JNJ-46356479 2.5, 5, and 10 mg/kg s.c. with LTG 12.5, 25, and 50 mg/kg i.p.
Administration:

s.c. for JNJ-46356479 and i.p. for LTG; single injection; 0.5 h before testing for JNJ-46356479 and 1 h before testing for LTG
Result:

For JNJ-46356479 + LTG at 2.5 + 12.5 mg/kg, protected/n was 0/8 and rotarod failures were 1/8.
At 5 + 25 mg/kg, protected/n was 6/8 and rotarod failures were 0/8.
At 10 + 50 mg/kg, protected/n was 8/8 and rotarod failures were 2/8.
ED₅₀,exp and ED₅₀,add for the JNJ-46356479/LTG combination did not differ.

Animal Model:

C57BL/6J (male and female; Veh+JNJ group N=5, 2 males and 3 females; started at adulthood PND80)^[6]
Dosage:

10 mg/kg
Administration:

s.c.; once daily; from PND 80 through the study period
Result:

In PFC, caspase-3 protein levels were 42.54 densitometry arbitrary units in the Veh+JNJ group.
In PFC, the Bax/Bcl-2 ratio was 64.97 in the Veh+JNJ group.
No significant differences in Bax protein levels were seen in any brain tissue.

Animal Model:

C57BL/6J (male and female; model+JNJ group N=6, 3 males and 3 females; started at adulthood PND80)^[6]
Dosage:

10 mg/kg
Administration:

s.c.; once daily; from PND 80 through the study period
Result:

In PFC, Bcl-2 protein levels were 119 densitometry arbitrary units in the model+JNJ group; JNJ administration partially restored the induced reduction in Bcl-2.
The Bax/Bcl-2 ratio in PFC and HPC was partially restored to control values in induced animals that received JNJ.
No significant differences in Bax protein levels were seen in any brain tissue.

Related Protocols :

Chemical Information

CAS. Nr. 1254979-66-2
Appearance Solid
Molecular Weight 451.44
Formel C₂₂H₂₂F₅N₅
Color White to off-white
SMILES

FC1=CC=C(C(F)=C1)N2CCN(CC2)CC3=C(C4=NN=C(N4C=C3)CC5CC5)C(F)(F)F
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 100 mg/mL (221.51 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.2151 mL

11.0757 mL

22.1513 mL

5 mM

0.4430 mL

2.2151 mL

4.4303 mL

10 mM

0.2215 mL

1.1076 mL

2.2151 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (5.54 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (5.54 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (5.54 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (296 KB)
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Korean - KR (394 KB)
- Portuguese - PT (394 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Olivares-Berjaga D, et al. Effectiveness of positive allosteric modulators of metabotropic glutamate receptor 2/3 (mGluR2/3) in animal models of schizophrenia. Translational psychiatry. 2025 Jan 14;15(1):11.

[2]. Leurquin-Sterk G, et al. What We Observe In Vivo Is Not Always What We See In Vitro: Development and Validation of 11C-JNJ-42491293, A Novel Radioligand for mGluR2. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2017 Jan;58(1):110-116.

[3]. Martínez-Pinteño A, et al. Early treatment with JNJ-46356479, a mGluR2 modulator, improves behavioral and neuropathological deficits in a postnatal ketamine mouse model of schizophrenia. Biomedicine & Pharmacotherapy. 2023 Feb 1;158:114079.

[4]. Martínez-Pinteño A, et al. Effects of JNJ-46356479 and clozapine on VGLUT1 and GAD65/67 brain levels and expression of genes related to glutamate and GABA in mice postnatally exposed to ketamine. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie. 2025 Nov;192:118639.

[5]. Metcalf CS, et al. Potent and selective pharmacodynamic synergy between the metabotropic glutamate receptor subtype 2-positive allosteric modulator JNJ-46356479 and levetiracetam in the mouse 6-Hz (44-mA) model. Epilepsia. 2018 Mar;59(3):724-735.

[6]. Olivares-Berjaga D, et al. Effects of the PAM of mGluR2, JNJ-46356479, on brain apoptotic protein levels in a mouse model of schizophrenia. Progress in neuro-psychopharmacology & biological psychiatry. 2024 Apr 20;131:110955.

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.2151 mL	11.0757 mL	22.1513 mL	55.3783 mL
	5 mM	0.4430 mL	2.2151 mL	4.4303 mL	11.0757 mL
	10 mM	0.2215 mL	1.1076 mL	2.2151 mL	5.5378 mL
	15 mM	0.1477 mL	0.7384 mL	1.4768 mL	3.6919 mL
	20 mM	0.1108 mL	0.5538 mL	1.1076 mL	2.7689 mL
	25 mM	0.0886 mL	0.4430 mL	0.8861 mL	2.2151 mL
	30 mM	0.0738 mL	0.3692 mL	0.7384 mL	1.8459 mL
	40 mM	0.0554 mL	0.2769 mL	0.5538 mL	1.3845 mL
	50 mM	0.0443 mL	0.2215 mL	0.4430 mL	1.1076 mL
	60 mM	0.0369 mL	0.1846 mL	0.3692 mL	0.9230 mL
	80 mM	0.0277 mL	0.1384 mL	0.2769 mL	0.6922 mL
	100 mM	0.0222 mL	0.1108 mL	0.2215 mL	0.5538 mL

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

JNJ-46356479

Alle mGluR Isoform-spezifische Produkte anzeigen